Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
Background: The experience of Kymriah® and Yescarta® provides real-world examples of how health-care systems approach and manage the reimbursement of one-off, high-cost, cell, and gene therapies, and the decision uncertainty and affordability challenges they present. Objective: To provide an overvie...
Guardado en:
Autores principales: | , , |
---|---|
Formato: | Libro |
Publicado: |
Taylor & Francis Group,
2020-01-01T00:00:00Z.
|
Materias: | |
Acceso en línea: | Connect to this object online. |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Internet
Connect to this object online.3rd Floor Main Library
Número de Clasificación: |
A1234.567 |
---|---|
Copia 1 | Disponible |